Skip to main content Skip to search Skip to main navigation

EC: EU MDR in force along with Q&A

Finally the date has come: as of 26 May 2021 the EU rules on medical devices (EU MDR) entered into force. Following a one year postponement due to COVID-19, this regulation is considered a big step forward to improve the safety and quality of medical devices. There are, however, still plenty of uncertainties for their manufacturers, but there is also a saying that every journey begins with single steps.

Along with the announcement, the European Commission (EC) issued a Q&A document on the application of MDR.

The document summarizes

  • the many patient benefits from a new approach for medical device oversight
  • delineates which products are affected by the new regulation and in what way
  • general information on the validity of products certified under the old scheme for which a transitional period is granted until May 2024, or
  • the role of the Notified Bodies and the state of play on EUDAMED

With the content being held rather general resembling a basic overview, it is noted, that some MDR provisions will not be in place until 2025, to allow a smooth transition. The regulation for in vitro diagnostic medical devices will enter into force on 26 May 2022.


Source:

EC: Press Corner

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EU: First Four EUDAMED Modules Mandatory from 28 May 2026

EU: First Four EUDAMED Modules Mandatory from 28 May 2026

With Commission Decision (EU) 2025/2371, the European Commission has formally declared that the first four EUDAMED modules meet the required functional specifications. Publication in the OJEU on 27 November 2025 activates the six-month transition period foreseen in Regulation (EU) 2024/1860.

Read more
Swissmedic: Digital Package Leaflet Instead of Paper

Swissmedic: Digital Package Leaflet Instead of Paper

From 1 December 2025, medicines intended solely for use by healthcare professionals no longer require a printed package leaflet. Instead, a QR code on the outer packaging must provide direct access to the professional information.

Read more
EMA: 6 New Nitrosamines for Appendix 1

EMA: 6 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.

Read more
How is a QRM process initiated?

How is a QRM process initiated?

You can view the answer here:
Read more
FDA: Updated Pre-RFD Guidance for Combination Products

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.
Read more
EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.
Read more
Previous
Next